Takeda may be poised to expand IBS treatment category

Share this article:

Data about Takeda's Phase III ulcerative colitis/Crohn's disease medication indicate the drug could join the treatment mix that includes brand such as AbbVie's Humira, Johnson & Johnson's Remicade and UCB's Cimzia.

The company announced the results of the two Phase III trials Wednesday, and published the findings Thursday in the New England Journal of Medicine. Takeda put the drug up for FDA review in June.

The studies showed ulcerative colitis patients had an improved clinical response within six weeks, compared to placebo and clinical remission at 52 weeks. Additional benefits included mucosal healing. Crohn's Disease patients had statistically significant improvement at six weeks. The clinical trial used patients who had failed on other medications. While not unusual, Bloomberg points out that this patient subset is significant because around 10% of patients with these conditions, which are included in the category known as Irritable Bowel Syndrome or Irritable Bowel Disease, need to switch medications because the prescriptions stop working. Even with Humira in its pocket, AbbVie continues to seek new treatments, and recently extended its Crohn's disease collaboration with Galapagos, to push exploration of GLPG0634 treatment into Phase II testing.

The roster of treatments for Crohn's and ulcerative colitis are almost indistinguishable, and the financial benefits follow similar trajectories: AbbVie's Humira has been enough of a blockbuster to carry its being spun-off from Abbott this year. Its list of approved indications includes Crohn's, ulcerative colitis, rheumatoid arthritis, plaque psoriasis and psoriatic arthritis, among others, and earned the company $2.6 billion in sales for the first six months of the year. Johnson & Johnson's Remicade's list of approved uses mirrors those of AbbVie's, and earned the drug maker almost $5 billion in sales for the first six months of the year.
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Channel

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...